Stock Events

Stock Events

Outlook Therapeutics 

€0.17
102
+€0+0.87% Thursday 07:55

Statistics

Day High
0.17
Day Low
0.17
52W High
2.48
52W Low
0.17
Volume
-
Avg. Volume
-
Mkt Cap
14.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.85
-0.58
-0.32
-0.05
Expected EPS
-0.10414799999999999
Actual EPS
N/A

Financials

-4,478.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.4MRevenue
-107.66MNet Income

Analyst Ratings

$1.90Average Price Target
The highest estimate is 4.55.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 41O.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly with treatments for eye diseases, directly competing with Outlook Therapeutics' eye therapy products.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. focuses on the development of gene therapy products for eye diseases, offering direct competition to Outlook Therapeutics' gene therapy approaches for ocular diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has a strong presence in the ophthalmology market, including therapies for macular degeneration and other eye conditions, competing with Outlook Therapeutics.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies Inc., through its eye health division, provides a wide range of products for eye conditions, directly competing with Outlook Therapeutics.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, after acquiring Allergan, has become a significant player in the eye care market, offering products that compete with Outlook Therapeutics' treatments.
Rogers
ROG
Mkt Cap1.57B
Roche Holding AG, with its ophthalmology division, offers treatments for various eye diseases, competing with Outlook Therapeutics in the broader eye care market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has investments in treatments for eye diseases, including therapies for retinal disorders, making it a competitor to Outlook Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division, develops treatments for eye health, including surgery and vision care, competing with Outlook Therapeutics.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc, with its healthcare portfolio, includes treatments for eye conditions, indirectly competing with Outlook Therapeutics in the healthcare market.

About

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Show more...
CEO
ISIN
US69012T3059
WKN
000A4046T

Listings

F
DE
41O.F
XNAS
US
OTLK
BOATS
BOATS
OTLK.BOATS

0 Comments

Share your thoughts

FAQ

What is Outlook Therapeutics stock price today?▼
The current price of 41O.F is €0.17 EUR — it has increased by +0.87% in the past 24 hours. Watch Outlook Therapeutics stock price performance more closely on the chart.
What is Outlook Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Outlook Therapeutics stocks are traded under the ticker 41O.F.
Is Outlook Therapeutics stock price growing?▼
41O.F stock has fallen by -1.53% compared to the previous week, the month change is a -50.51% fall, over the last year Outlook Therapeutics has showed a -83.58% decrease.
What is Outlook Therapeutics market cap?▼
Today Outlook Therapeutics has the market capitalization of 14.45M
When is the next Outlook Therapeutics earnings date?▼
Outlook Therapeutics is going to release the next earnings report on May 14, 2026.
What were Outlook Therapeutics earnings last quarter?▼
41O.F earnings for the last quarter are -0.19 EUR per share, whereas the estimation was -0.19 EUR resulting in a +2.94% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Outlook Therapeutics revenue for the last year?▼
Outlook Therapeutics revenue for the last year amounts to 2.4M EUR.
What is Outlook Therapeutics net income for the last year?▼
41O.F net income for the last year is -107.66M EUR.
When did Outlook Therapeutics complete a stock split?▼
The last stock split for Outlook Therapeutics was on March 14, 2024 with a ratio of 1:20.